Loading...
XTAI4142
Market cap255mUSD
Dec 25, Last price  
19.90TWD
1D
0.25%
1Q
-27.21%
Jan 2017
-8.73%
IPO
-46.52%
Name

Adimmune Corp

Chart & Performance

D1W1MN
XTAI:4142 chart
P/E
—
P/S
4.70
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.34%
Rev. gr., 5y
16.77%
Revenues
1.79b
-20.72%
1,369,929,000834,775,000290,363,000387,162,000414,093,000480,506,000290,737,000606,725,000562,743,000822,366,0001,299,689,0001,869,147,0001,641,061,0002,251,624,0001,785,094,000
Net income
-640m
L
588,882,000161,307,000-471,318,000-603,680,000-600,453,000-614,422,000-761,087,000-595,352,000-760,176,000-609,117,000-321,737,0001,241,246,00028,378,000146,216,000-639,891,000
CFO
-892m
L+205.64%
600,423,000516,393,000-293,775,000-409,475,000-568,636,000-417,354,000-373,817,000-773,530,0006,874,000-601,740,000-261,703,0002,321,723,000-480,517,000-291,965,000-892,349,000
Dividend
Sep 14, 20210.5 TWD/sh
Earnings
Jun 20, 2025

Profile

Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.
URL
https://www.adimmune.com.tw/
IPO date
Sep 29, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,785,094
-20.72%
2,251,624
37.21%
1,641,061
-12.20%
Cost of revenue
2,113,965
2,153,071
1,847,867
Unusual Expense (Income)
NOPBT
(328,871)
98,553
(206,806)
NOPBT Margin
4.38%
Operating Taxes
10,000
(14,093)
Tax Rate
10.15%
NOPAT
(328,871)
88,553
(192,713)
Net income
(639,891)
-537.63%
146,216
415.24%
28,378
-97.71%
Dividends
(214,754)
Dividend yield
1.12%
Proceeds from repurchase of equity
(17,264)
(309,802)
BB yield
0.12%
2.03%
Debt
Debt current
1,224,641
161,712
48,215
Long-term debt
1,981,404
2,179,198
1,286,026
Deferred revenue
Other long-term liabilities
1,937
2,351
7,946
Net debt
638,625
(620,020)
(1,439,099)
Cash flow
Cash from operating activities
(892,349)
(291,965)
(480,517)
CAPEX
(221,457)
(419,625)
(845,258)
Cash from investing activities
(366,563)
(322,066)
(728,838)
Cash from financing activities
859,296
823,194
(222,892)
FCF
(772,476)
(629,641)
(1,851,933)
Balance
Cash
2,485,008
2,972,590
2,891,017
Long term investments
82,412
(11,660)
(117,677)
Excess cash
2,478,165
2,848,349
2,691,287
Stockholders' equity
5,234,698
5,988,315
5,577,422
Invested Capital
6,443,968
5,961,408
5,069,975
ROIC
1.61%
ROCE
1.12%
EV
Common stock shares outstanding
421,508
427,679
429,602
Price
33.15
-6.88%
35.60
-20.27%
44.65
-20.41%
Market cap
13,972,990
-8.23%
15,225,372
-20.63%
19,181,730
-16.61%
EV
14,914,681
15,026,417
18,026,351
EBITDA
(104,746)
357,869
19,107
EV/EBITDA
41.99
943.44
Interest
33,426
22,592
14,688
Interest/NOPBT
22.92%